

Please try another search
(Reuters) -Abbott Laboratories' Michigan plant, which was at the center of the U.S. baby formula shortage last year, faces a criminal investigation by the Justice Department, the Wall Street Journal reported on Friday.
Panicked parents emptied baby formula aisles at supermarkets last year as a recall of formulas by Abbott due to complaints of bacterial infections exacerbated a shortage that began due to pandemic-induced supply chain issues.
The White House intervened to address the shortage.
Attorneys with the Justice Department's consumer-protection branch are conducting the criminal investigation, the WSJ report said, citing people familiar with the matter.
"DOJ has informed us of its investigation and we're cooperating fully," an Abbott spokesman told Reuters, without commenting further on the nature of the probe. The DOJ did not immediately respond to a request for comment.
In February 2022, Abbott, the biggest U.S. supplier of baby formula, recalled Similac and other infant formula products produced at the Michigan facility after reports of bacterial infections in babies who had consumed products made there.
The U.S. Food and Drug Administration found "shocking" results during an inspection such as cracks in vital equipment, a lack of adequate hand-washing and evidence of previous bacterial contamination. The regulator and the company later reached an agreement that allowed the plant to reopen.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.